• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    11/8/24 9:13:26 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email
    SC 13G/A 1 d894018dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Bioventus Inc.

    (Name of Issuer)

    Class A Common Stock

    (Title of Class of Securities)

    09075A108

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 09075A108    Schedule 13G    Page 1 of 8

     

     1   

     Names of Reporting Persons

     

     Spindletop Healthcare Capital, L.P.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     0.0%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 09075A108    Schedule 13G    Page 2 of 8

     

     1   

     Names of Reporting Persons

     

     Spindletop Capital GP, L.P.

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     0.0%

    12  

     Type of Reporting Person

     

     PN


    CUSIP No. 09075A108    Schedule 13G    Page 3 of 8

     

     1   

     Names of Reporting Persons

     

     Spindletop GP Management, LLC

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     0.0%

    12  

     Type of Reporting Person

     

     OO


    CUSIP No. 09075A108    Schedule 13G    Page 4 of 8

     

     1   

     Names of Reporting Persons

     

     Evan S. Melrose

     2  

     Check the Appropriate Box if a Member of a Group

     (a) ☐  (b) ☐

     

     3  

     SEC Use Only

     

     4  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5   

     Sole Voting Power

     

     0

       6  

     Shared Voting Power

     

     0

       7  

     Sole Dispositive Power

     

     0

       8  

     Shared Dispositive Power

     

     0

     9   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     0

    10  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     Not Applicable

    11  

     Percent of Class Represented by Amount in Row 9

     

     0.0%

    12  

     Type of Reporting Person

     

     IN


    CUSIP No. 09075A108    Schedule 13G    Page 5 of 8

     

    ITEM 1. (a)

    Name of Issuer:

    Bioventus Inc. (the “Issuer”).

     

        (b)

    Address of Issuer’s Principal Executive Offices:

    4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703

     

    ITEM 2. (a)

    Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

      Spindletop Healthcare Capital, L.P.

      Spindletop Capital GP, L.P.

      Spindletop GP Management, LLC

      Evan S. Melrose

     

        (b)

    Address or Principal Business Office:

    The principal business address of each of the Reporting Persons is 3571 Far West Boulevard, PMB #108, Austin, Texas 78731.

     

        (c)

    Citizenship of each Reporting Person is:

    Evan S. Melrose is a citizen of the United States. Each of the other Reporting Persons is organized under the laws of the state of Delaware.

     

        (d)

    Title of Class of Securities:

    Class A Common Stock, $0.001 par value per share (“Class A Common Stock”).

     

        (e)

    CUSIP Number:

    09075A108

     

    ITEM 3.

    Not applicable.


    CUSIP No. 09075A108    Schedule 13G    Page 6 of 8

     

    ITEM 4.

    Ownership.

    (a-c)

    This amendment to Schedule 13G is being filed to report that, as of the date hereof, the Reporting Persons do not beneficially own any shares of Common Stock.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 09075A108    Schedule 13G    Page 7 of 8

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 8, 2024

     

    Spindletop Healthcare Capital, L.P.
    By:   Spindletop Capital GP, L.P., its general partner
    By:   Spindletop GP Management, LLC, its general partner
    By:   /s/ Evan Melrose
    Name:   Evan Melrose
    Title:   Manager
    Spindletop Capital GP, L.P.
    By:   By: Spindletop GP Management, LLC, its general partner
    By:   /s/ Evan Melrose
    Name:   Evan Melrose
    Title:   Manager
    Spindletop GP Management, LLC
    By:   /s/ Evan Melrose
    Name:   Evan Melrose
    Title:   Manager
    Evan S. Melrose
    /s/ Evan S. Melrose


    CUSIP No. 09075A108    Schedule 13G    Page 8 of 8

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $BVS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    3/15/2022$30.00Buy
    Craig Hallum
    3/11/2022$20.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives.

      1/7/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. converted options into 7,575 shares, increasing direct ownership by 11% to 79,620 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/10/25 5:49:16 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Bartholdson John A. converted options into 26,493 shares, increasing direct ownership by 58% to 72,045 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/5/25 9:22:27 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Sutter Martin P converted options into 26,493 shares, increasing direct ownership by 45% to 85,241 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/4/25 9:30:50 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      8/20/24 6:16:00 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    SEC Filings

    See more
    • Bioventus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Bioventus Inc. (0001665988) (Filer)

      6/4/25 4:16:09 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Bioventus Inc.

      SD - Bioventus Inc. (0001665988) (Filer)

      6/2/25 5:10:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bioventus Inc.

      10-Q - Bioventus Inc. (0001665988) (Filer)

      5/6/25 7:38:47 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bioventus upgraded by Analyst with a new price target

      Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

      12/17/24 7:32:13 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00

      12/7/23 6:14:32 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Bioventus from Hold to Buy and set a new price target of $6.00 from $4.00 previously

      8/9/23 7:43:55 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bioventus Appoints Mark Singleton as Chief Financial Officer

      DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

      2/28/22 7:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus Appoints Michelle McMurry-Heath to Board of Directors

      DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

      12/21/21 9:25:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BVS
    Financials

    Live finance-specific insights

    See more
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      11/8/24 9:13:26 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      7/15/24 5:15:58 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      2/14/24 4:51:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

      DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

      10/29/24 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care